9 February 2021
Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.
27 October 2020
Congratulations are in order for Associate Professor Samira Lakhal-Littleton, who has been awarded a Senior Non-Clinical Fellowship by the Medical Research Council to further her lab's work exploring the implications of the cardiac hepcidin/ferroportin axis for the management of iron deficiency in heart failure.
11 October 2020
Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.
4 September 2020
The partnership will produce the first ever British Society of Echocardiography National review of Stress Echocardiography Practice (BSE N-STEP).
15 July 2020
The number of admissions to hospital with heart attacks fell by 35% by the end of March.
26 May 2020
DPAG researchers have collaborated on an international study that demonstrates a detailed mechanistic understanding of how the anti-malaria drug, Hydroxychloroquine, combined with antibiotics, can cause adverse cardiac side-effects in COVID-19 patients. This gives weight to US Federal advice against using this combined treatment.
27 April 2020
New collaborative research from the Mommersteeg Group and MRC WIMM researchers shows that a protein called Runx1 plays a significant role in the formation of the cardiac scar that forms after the heart is injured, a scar that is known to inhibit heart regeneration. In the zebrafish, a freshwater fish known to be able to fully regenerate its heart after damage, they show that the absence of Runx1 results in enhanced regeneration. This indicates a potential new therapeutic target for heart repair.
14 January 2020
Up to 30,000 lives could be saved over the next decade thanks to a proposed pioneering government collaboration with pharmaceutical company Novartis to tackle heart disease – a leading cause of death in the UK.
8 January 2020
For many years, we have been using beta-blockers to neutralise a specific stress hormone and prevent dangerous heart rhythms following a heart attack. However, a new study led by Associate Professor Neil Herring and published in the European Heart Journal has uncovered evidence for an additional stress hormone acting as a key trigger for dangerous heart rhythms that is not currently targeted by these drugs.